89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this multicenter imaging sub study is to evaluate the biodistribution and
organ pharmacokinetics of 89Zr-MMOT0530A in patients with unresectable pancreatic or
platinum-resistant ovarian cancer. MMOT0530A is a monoclonal antibody that targets an antigen
overexpressed in pancreatic and ovarian cancer. Subsequent to imaging with 89Zr-MMOT0530A,
patients will be treated with DMOT4039A in the DMO4993g protocol (clinicaltrials.gov
identifier NCT01469793) after this study. DMOT4039A is an antibody-drug conjugate composed of
the monoclonal antibody MMOT0530A and the mitotic agent monomethyl auristatin (MMAE). By
imaging patients with the monoclonal antibody MMOT0530A before treatment, the correlation
between tumor uptake of 89Zr-MMOT0530A and response to DMOT4039A therapy will be assessed.